China Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
China Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
Tianjin, China1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Recruiting | Phase 2 | 2024-07-22 | NCT06513234 |